X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (947) 947
Newspaper Article (90) 90
Publication (90) 90
Patent (42) 42
Book / eBook (28) 28
Book Chapter (7) 7
Conference Proceeding (5) 5
Book Review (3) 3
Dissertation (3) 3
Magazine Article (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (378) 378
index medicus (252) 252
hematology (249) 249
male (190) 190
oncology (190) 190
female (188) 188
middle aged (178) 178
adult (163) 163
aged (159) 159
imatinib mesylate (147) 147
chronic myelogenous leukemia (144) 144
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (129) 129
benzamides (113) 113
pyrimidines - therapeutic use (107) 107
leukemia (103) 103
chronic myeloid-leukemia (100) 100
chronic myeloid leukemia (99) 99
imatinib (97) 97
antineoplastic agents - therapeutic use (95) 95
treatment outcome (90) 90
piperazines - therapeutic use (89) 89
leukemia, myelogenous, chronic, bcr-abl positive - genetics (87) 87
cancer (83) 83
aged, 80 and over (79) 79
fusion proteins, bcr-abl - genetics (78) 78
bcr-abl (76) 76
medicine & public health (71) 71
therapy (70) 70
hemic and lymphatic diseases (68) 68
dasatinib (65) 65
protein kinase inhibitors - therapeutic use (63) 63
adolescent (61) 61
mutation (58) 58
care and treatment (54) 54
prognosis (54) 54
analysis (52) 52
research (50) 50
cml (49) 49
pyrimidines - administration & dosage (49) 49
young adult (48) 48
abridged index medicus (45) 45
leukemia, myelogenous, chronic, bcr-abl positive - pathology (42) 42
animals (40) 40
cancer research (40) 40
tyrosine kinase inhibitors (40) 40
interferon-alpha (39) 39
chronic-phase (38) 38
chemotherapy (37) 37
follow-up (37) 37
internal medicine (37) 37
nilotinib (37) 37
pyrimidines - adverse effects (37) 37
acute lymphoblastic-leukemia (36) 36
follow-up studies (36) 36
piperazines - administration & dosage (36) 36
pyrimidines - pharmacology (35) 35
antineoplastic agents (34) 34
drug resistance, neoplasm (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (34) 34
survival (34) 34
antineoplastic agents - administration & dosage (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
hematology, oncology and palliative medicine (33) 33
disease-free survival (32) 32
piperazines - pharmacology (32) 32
protein-tyrosine kinases - antagonists & inhibitors (32) 32
stem cells (32) 32
blast crisis (31) 31
fusion proteins, bcr-abl - metabolism (31) 31
microbiology (31) 31
protein kinase inhibitors - administration & dosage (31) 31
cells (30) 30
chemistry (30) 30
leukemia, myelogenous, chronic, bcr-abl positive - therapy (30) 30
philadelphia-chromosome (30) 30
antineoplastic agents - adverse effects (29) 29
biochemistry (29) 29
leukemia, myelogenous, chronic, bcr-abl positive - mortality (29) 29
retrospective studies (29) 29
transplantation (29) 29
antimitotic agents (28) 28
beer (28) 28
compositions or test papers therefor (28) 28
condition-responsive control in microbiological orenzymological processes (28) 28
enzymology (28) 28
measuring or testing processes involving enzymes, nucleicacids or microorganisms (28) 28
metallurgy (28) 28
mutation or genetic engineering (28) 28
neoplasms (28) 28
polymerase-chain-reaction (28) 28
processes of preparing such compositions (28) 28
resistance (28) 28
spirits (28) 28
thiazoles - therapeutic use (28) 28
vinegar (28) 28
wine (28) 28
drug resistance, neoplasm - genetics (27) 27
drug therapy (27) 27
medicine (27) 27
patients (27) 27
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Applied Energy, ISSN 0306-2619, 01/2018, Volume 209, pp. 355 - 382
This paper analyses the integration of air open-loop photovoltaic thermal systems on the façade of high-rise buildings, with a special focus on their active... 
Energy performance analysis | Multi-floor building | Building integrated photovoltaic thermal system | Dynamic simulation modelling | Case studies | Weather | Energy consumption | Energy efficiency | Analysis
Journal Article
Energy & Buildings, ISSN 0378-7788, 04/2018, Volume 165, pp. 293 - 300
The first application of a commercially available aerogel based rendering to the external façades of a 30-m-high building made of prefabricated concrete panels... 
Infrared thermography | Retrofit | U-value | In-situ measurement | Aerogel based rendering | Insulating rendering | Energy-efficient | Prefabricated concrete panel | EXTERIOR | ENERGY & FUELS | PERFORMANCE | PLASTER | ENGINEERING, CIVIL | CONSTRUCTION & BUILDING TECHNOLOGY | INSULATION
Journal Article
Applied Mechanics and Materials, ISSN 1662-7482, 11/2018, Volume 885, pp. 211 - 223
High-rise water supply systems provide water flow and suitable pressure in all levels of tall buildings. To design such state-of-the-art systems, the... 
Tall buildings | Water supply | Optimal control | Water supply systems | Water flow | Nonlinear programming | Water shortages | Failure | Optimization | Resilience
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2011, Volume 2011, Issue 1, pp. 128 - 135
Journal Article
Detail structure, 01/2016, Issue 1, pp. 46 - 53.
Project: Intesa Sanpaolo office building, Turin. Architect: Renzo Piano Building Workshop. Competition date: 2006; design and construction phase: 2006-2015. 
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 6, pp. 579 - 588
Journal Article
Zugl.: Leipzig, Universiẗat, Diss., 2004. 
Hochhaus
Dissertation
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2542 - 2551
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2408 - 2417
The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON-ALPHA | CHRONIC-PHASE | ABL TYROSINE KINASE | COMPLETE CYTOGENETIC REMISSION | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | ALPHA PLUS CYTARABINE | Follow-Up Studies | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Fusion Proteins, bcr-abl - blood | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Interferon alpha | Clinical trials | Bone marrow | Transplants & implants | Pharmaceutical industry | Leukemia | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article